Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.
Many vaccines require the use of an adjuvant to achieve immunity. So far, few adjuvants have advanced successfully through clinical trials to become part of licensed vaccines. Vaxfectin® (Vical, CA, USA) represents a next-generation adjuvant with promise as a platform technology, showing utility with both plasmid DNA (pDNA) and protein-based vaccines. This review describes the chemical, physical, preclinical and clinical development of Vaxfectin for pDNA-based vaccines. Also included is the preclinical development of Vaxfectin-adjuvanted protein- and peptide-based vaccines. The reader will gain knowledge of vaccine adjuvant development from bench to bedside. Vaxfectin has effectively boosted the immune response against a range of pDNA-expressed pathogenic antigens in preclinical models extending from rodents to non-human primates. In the clinic, Vaxfectin-adjuvanted pDNA-based H5N1 influenza vaccines have been shown to be well tolerated and to result in durable immune responses within the predicted protective range reported for protein-based vaccines.